Blog
RSS FeedPosted by Michael Wonder on 11 Jan 2021
Myriad Genetics receives first reimbursement decision for myChoice diagnostic system in Japan, enabling women with ovarian cancer to benefit from treatment with Zejula
8 January 2021 - Myriad Genetics announced today that it received its first reimbursement decision for the Myriad myChoice Diagnostic System, ...
Posted by Michael Wonder on 05 Jan 2021
Daiichi Sankyo submits application for oncolytic virus teserpaturev (G47∆) for treatment of patients with malignant glioma in Japan
5 January 2020 - Daiichi Sankyo and the University of Tokyo are collaboratively developing teserpaturev, which has received SAKIGAKE designation and ...
Posted by Michael Wonder on 28 Dec 2020
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
28 December 2020 - Approvals based on the PAOLA-1, PROfound and POLO Phase III trials ...
Posted by Michael Wonder on 17 Dec 2020
Japan to lower drug prices to reduce medical costs
17 December 2020 - Japanese Finance Minister Taro Aso and health minister Norihisa Tamura agreed Thursday to reduce state-set prices ...
Posted by Michael Wonder on 30 Nov 2020
Astellas receives approval of Evrenzo (roxadustat) in Japan for the treatment of anaemia of chronic kidney disease in adult patients not on dialysis
27 November 2020 - Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with ...
Posted by Michael Wonder on 30 Nov 2020
Forxiga approved in Japan for chronic heart failure
30 November 2020 - Forxiga is the first SGLT2 inhibitor approved in Japan for chronic heart failure with reduced ejection ...
Posted by Michael Wonder on 19 Nov 2020
Brickell Biotech announces launch date for sofpironium bromide 5% gel (Ecclock) in Japan by its development partner, Kaken Pharmaceutical
18 November 2020 - Kaken plans to launch Ecclock for the treatment of primary axillary hyperhidrosis in Japan on 26 November ...
Posted by Michael Wonder on 19 Nov 2020
Kyowa Kirin announces approval for partial change of rituximab biosimilar received by Sandoz in Japan
18 November 2020 - Kyowa Kirin today announced that Sandoz KK, its strategic partner of the anti-CD20 monoclonal antibody rituximab ...
Posted by Michael Wonder on 20 Oct 2020
Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
19 October 2020 - Fujifilm said it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in ...
Posted by Michael Wonder on 28 Sep 2020
Ultomiris (ravulizumab) receives approval in Japan for atypical haemolytic uraemic syndrome in adults and children
25 September 2020 - Ultomiris is the first and only long-acting C5 inhibitor for atypical haemolytic uraemic syndrome, reducing the treatment ...
Posted by Michael Wonder on 28 Sep 2020
Enhertu approved in Japan for the treatment of patients with HER2 positive metastatic gastric cancer
25 September 2020 - Approval of SAKIGAKE designated medicine is based on pivotal phase 2 DESTINY-Gastric01 trial and represents second approval ...
Posted by Michael Wonder on 28 Sep 2020
Opdivo and Yervoy combination therapy approved in Japan to expand use for the treatment of microsatellite instability high colorectal cancer, and Opdivo for additional dosage and administration in monotherapy dosing regimen
25 September 2020 - Ono Pharmaceutical and Bristol-Myers Squibb announced today that the companies have received approval for combination therapy ...
Posted by Michael Wonder on 25 Aug 2020
Imfinzi approved in Japan for the treatment of extensive-stage small cell lung cancer
21 August 2020 - Only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with ...
Posted by Michael Wonder on 03 Aug 2020
Japan and Pfizer reach COVID-19 vaccine deal to treat 60 million people
1 August 2020 - The government has reached a deal to have Pfizer and BioNTech supply 120 million doses of ...
Posted by Michael Wonder on 29 Jul 2020
Teva announces new drug application filing in Japan for Ajovy (fremanezumab) injection
29 July 2020 - Teva Pharmaceutical Industries today announced Otsuka has submitted an application to the Pharmaceuticals and Medical Devices Agency ...